Ergomed Aktie - WKN: A117XM

Seite 1 von 5
Neuester Beitrag: 14.05.21 23:12
Eröffnet am: 06.10.15 09:41 von: youmake222 Anzahl Beiträge: 103
Neuester Beitrag: 14.05.21 23:12 von: StockWatch. Leser gesamt: 22.917
Forum: Börse   Leser heute: 30
Bewertet mit:

Seite: < 1 | 2 | 3 | 4 | 5 5  >  

558659 Postings, 2512 Tage youmake222Ergomed Aktie - WKN: A117XM

06.10.15 09:41
Ergomed Aktie




77 Postings ausgeblendet.
Seite: < 1 | 2 | 3 | 4 | 5 5  >  

40 Postings, 1524 Tage PeppaPigKauf-Empfehling

06.12.20 20:01
Sharecast News | 06 Dec, 2020

The Mail on Sunday's Midas column recommended readers 'buy' shares of pharmacovigilance specialist Ergomed.

303 Postings, 627 Tage StockWatchNowErgomed Acquires MedSource

26.01.21 00:24

40 Postings, 1524 Tage PeppaPigWeiter geht's nach oben

26.01.21 13:12

303 Postings, 627 Tage StockWatchNowstrong top line growth

27.01.21 10:54
Ergomed reveal 'another good year, with strong top line growth and overall financial performance'  

303 Postings, 627 Tage StockWatchNowresults 2020

23.03.21 07:59
releasing the results for the Full Year of 2020. We will be hosting a presentation for analysts and investors at 9am GMT. Visit the investor site to access the presentation, which will be uploaded today.  

40 Postings, 1524 Tage PeppaPigErgebnisse 2020

23.03.21 20:00

303 Postings, 627 Tage StockWatchNowErgomed highlight 'year of strong delivery' both f

24.03.21 11:46
Ergomed highlight 'year of strong delivery' both financially and strategically  

303 Postings, 627 Tage StockWatchNowWe have started 2021 in a strong position

30.03.21 22:41
Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “Ergomed made exceptional progress in delivering its strategy in 2020, despite the challenges of the COVID-19 pandemic. The resilience and robustness of our global services business was demonstrated by our continued strong organic growth whilst completing key strategic acquisitions in the US in both our pharmacovigilance and CRO businesses. We have started 2021 in a strong position, focused on our vision to achieve global leadership in specialised pharmaceutical services addressing unmet medical needs and patient safety.”  

303 Postings, 627 Tage StockWatchNowErgomed (ERGO) - Richard Barfield, CFO

31.03.21 21:14
Ergomed (ERGO) - Richard Barfield, CFO  

303 Postings, 627 Tage StockWatchNowErgomed

07.04.21 13:15
.... es ist wieder so schön ruhig -  der nächste Deal steht bestimmt schon in den Startlöchern ;)  

303 Postings, 627 Tage StockWatchNowPharmacovigilance Impact Series

08.04.21 13:51
Ergomeds  “Pharmacovigilance Impact Series” continues!
The Impact of Covid-19 on Pharmacovigilance

In this webinar, our expert speakers, Dr. Marcela Fialova and Dr. Hyankova Jana, will give insight into Covid’s impact on the EU and the UK pharmacovigilance processes, highlighting the challenges that the Pharmaceutical Industry has had to face and how they adapted.  

303 Postings, 627 Tage StockWatchNowMedSource and PSR Orphan Experts rebrand to Ergome

13.04.21 21:41
MedSource and PSR Orphan Experts rebrand to Ergomed
...successful integration of both PSR Orphan Experts and MedSource we will be aligning all our CRO businesses under the Ergomed name.  

303 Postings, 627 Tage StockWatchNowEurope Drug Safety Solutions and Pharmacovigilance

15.04.21 20:41
Europe Drug Safety Solutions and Pharmacovigilance Market​​​​​​​ 2020 Demand, Growth, Technology Trends, Key Findings And Forecasts By 2027  

303 Postings, 627 Tage StockWatchNowDouble Bottom

16.04.21 21:27
Das nächste Double Bottom ist gebaut - die ängstlichen sind draußen - wer hier verkauft, verbaut sich die Zukunftsaussichten in einem Wachstumsmarkt in dem nur wenige Player aktiv sind.  

303 Postings, 627 Tage StockWatchNowERGOMED - der nächste Sprung

23.04.21 20:07
ERGOMED - mit dem nächsten Deal steht der nächste Sprung bevor!

The Impact of Covid-19 on Pharmacovigilance

As a part of the Ergomed plc group, PrimeVigilance is the global leader in pharmacovigilance and specialized multi-lingual medical information services in 100+ countries.

Hosted By BioAlliance Video Network  

9 Postings, 24 Tage GabrieleebyjaLöschung

24.04.21 01:50

Zeitpunkt: 26.04.21 10:37
Aktionen: Löschung des Beitrages, Nutzer-Sperre für für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam



10 Postings, 24 Tage DoreenvrwcaLöschung

24.04.21 23:17

Zeitpunkt: 26.04.21 10:36
Aktionen: Löschung des Beitrages, Nutzer-Sperre für für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam



303 Postings, 627 Tage StockWatchNowWachstum - JAPAN!

26.04.21 10:27
Wachstum! -Ergomed opens PrimeVigilance business in Japan

The Japanese pharmaceutical market is the fourth-largest in the world after the US, the EU and China

“With a solid base of international clients in Japan, Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategically important Asia region.

“Following the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource, this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services specialist."  

303 Postings, 627 Tage StockWatchNowNews in japanisch

27.04.21 18:42

303 Postings, 627 Tage StockWatchNowBoard

29.04.21 12:25
Dr. Keltner brings over 30 years of experience across the life sciences sector, holding various senior positions with a particular focus on oncology and rare diseases. He has extensive experience of public and private financings, M&A, the formation of strategic partnerships and numerous transactions in the CRO, biotech and pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US rare disease company, he led multiple financing rounds, product launches and the eventual sale of the Company to Horizon Pharmaceuticals in 2016. He was also a member of the Board of Mannkind Corporation through its successful Nasdaq listing, and Immunovaccine Inc. through several successful fundraises.  

303 Postings, 627 Tage StockWatchNowShire & Genzyme

10.05.21 16:12
Mark Enyedy Appointed to Board as Non-Executive Director

Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.

Prior to ImmunoGen, Mr Enyedy served in various executive capacities at [b]Shire[/b] plc, including as [b]Executive Vice President and Head of Corporate Development[/b], a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at [b]Genzyme[/b] Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions.  

303 Postings, 627 Tage StockWatchNowshire & ImmunoGen

11.05.21 16:55

303 Postings, 627 Tage StockWatchNowEuropean Mediscience Awards 2021

12.05.21 15:09
NEWS:  European Mediscience Awards 2021. Ergomed has been shortlisted for “Best Communication Award” and “Company of the Year”.  

303 Postings, 627 Tage StockWatchNowNotice of AGM and Annual Report

14.05.21 23:12

Seite: < 1 | 2 | 3 | 4 | 5 5  >  
   Antwort einfügen - nach oben